Chinaa s slow approvals of biotech crops cost U.S. $7 billion, says industry group


Delays in Chinese approvals of imported genetically modified crops have cut U.S. gross domestic product by about $7 billion over the past five years by reducing sales of crops and other goods, an industry group that represents global seed companies said on Wednesday. The report by CropLife International indicates what is at stake for the administration of President Donald Trump as it seeks better access for U.S. GMO crops into China as part of a trade deal under discussion.



from Biotech News